Journal of Substance Abuse Treatment 2007;32(4):349-356. [doi: 10.1016/j.jsat.2006.09.006]
Gregory S. Brigham, PhD (Maryhaven, Inc., OV Node), Leslie Amass, PhD (Friends Research Institute, Inc, PR Node), Theresa M. Winhusen, PhD (Cincinnatti Addiction Research Center, OV Node), Judith M. Harrer, PhD (Cincinnati VA Medical Center), Alvin Pelt, MD (Maryhaven, Inc., OV Node).
The U.S. Federal Food and Drug Administration approved buprenorphine for drug abuse treatment in 2002, and it became available for clinical use in 2003. Maryhaven, a community treatment program, participated in National Institute on Drug Abuse Clinical Trials Network trial CTN-0001, evaluating buprenorphine-naloxone (BNX, Suboxone) short-term taper for medically managed opioid withdrawal in inpatient clinics, and later adopted this treatment. In a retrospective review, the first 64 patients treated with a BNX taper were compared with two groups of patients treated with clonidine before and after the implementation of the BNX program. Significantly more patients (about 80%) receiving BNX continued in further treatment compared to about 30% of those receiving clonidine. Patient outcomes are discussed in the context of the critical need for treatment continuation following detoxification. Common questions of potential adopters of the BNX taper are presented and addressed. Overall, BNX was readily integrated into the existing treatment service. (Article (Peer-Reviewed), PDF, English, 2007)
Keywords: Adoption of interventions | Buprenorphine | Buprenorphine/Naloxone | Clonidine | Dissemination | Opioid dependence | Pharmacological therapy | Retention - Treatment | Suboxone | Journal of Substance Abuse Treatment (journal)
Document No: 159, PMID: 17481458
Submitted by the CTN Dissemination Librarians, 1/4/2007.